CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research
Lu Y, Stoof J, Tanoé YR, Walsh N, Bijlsma MF, Lei H, Chen T, Grahovac J, Grützmann R, Pilarsky C (2025)
Publication Type: Journal article, Review article
Publication year: 2025
Journal
Book Volume: 114
Pages Range: 242-255
DOI: 10.1016/j.semcancer.2025.07.004
Abstract
CRISPR/Cas9 technology has emerged as a powerful tool in pancreatic ductal adenocarcinoma cancer (PDAC) research, facilitating the study of genes involved in cell signaling pathways, proliferation, migration, invasion, and chemotherapy resistance. In this review, we discuss the evolution of CRISPR technologies from sophisticated editing techniques to broad screening methods, examine the utility of isogenic models and genetically engineered mouse models (GEMMs). We also explore how CRISPR/Cas9 screens can reveal immune-tumor cell interactions, highlighting the multifaceted role of this technology in PDAC research. Moreover, we emphasize the use of CRISPR technology in diagnostics for CAR-T cell therapies, where CRISPR/Cas9 enhances the precision of targeting malignant cells while minimizing off-tumor effects.
Authors with CRIS profile
Yanxi Lu
Department of Surgery
Robert Grützmann
Lehrstuhl für Allgemein- und Viszeralchirurgie
Christian Pilarsky
Professur für Chirurgische Forschung
Involved external institutions
Dublin City University (DCU)
Ireland (IE)
University of Amsterdam
Netherlands (NL)
Chinese Academy of Sciences (CAS) / 中国科学院
China (CN)
Institute of Oncology and Radiology of Serbia / Institut za onkologiju i radiologiju Srbije
Serbia (RS)
Ireland (IE)
University of Amsterdam
Netherlands (NL)
Chinese Academy of Sciences (CAS) / 中国科学院
China (CN)
Institute of Oncology and Radiology of Serbia / Institut za onkologiju i radiologiju Srbije
Serbia (RS)
How to cite
APA:
Lu, Y., Stoof, J., Tanoé, Y.R., Walsh, N., Bijlsma, M.F., Lei, H.,... Pilarsky, C. (2025). CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. Seminars in Cancer Biology, 114, 242-255. https://doi.org/10.1016/j.semcancer.2025.07.004
MLA:
Lu, Yanxi, et al. "CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research." Seminars in Cancer Biology 114 (2025): 242-255.
BibTeX: Download